Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Orthostatic Hypotension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with severe orthostatic hypotension and other autonomic symptoms who do not meet criteria for one of our standard diagnoses~* non-smokers~* drug-free~* able to give informed consent~* free of pulmonary, renal, hematopoietic, hepatic and cardiac disease~Exclusion Criteria:~* medications affecting the autonomic nervous system~* any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic)~* anemia (Hct \< 30)~* women of childbearing age who are pregnant or nursing~* smokers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Droxidopa (Type: EXPERIMENTAL): Patients with known or suspected Dopamine beta-Hydroxylase Deficiency were administered Droxidopa doses of 25 mg, 50 mg, 100 mg, 200 mg, 250 mg or 300 mg up to three times daily. Supine and upright blood pressures were subsequently measured 60 to 240 minutes post-dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).